Yang Jianxin: Clinical Medical Scientist: "Walking a Circle"

Introduction: Yang Jianxin says he is a real clinical scientist if he has to characterise himself'If you have to characterize yourself, he's a real clinical medical scientist, ' says MrYang,he began with a background in clinical medicine, conducting extremely rigorous basic research (Ph.Dand postdoctoral research) in world-class laboratories, then in basic research on drug research at pharmaceutical companies, and then in translational research, then back to clinical research"I walked a whole lap, " he says/01/
"Go Faster" Ph.Dand postdoctoralYang Jian's new clinical medical background is traced back to his undergraduate Hubei Medical College Xianning Branch"It was a very small school, " he recalls, "when I first went to college, I couldn't write all 26 letters"
for historical reasons, the teachers from his faculty at that time were from Hubei Medical College or Tongji Medical University, the down-to-do old professor"Whether it's teaching or teaching people, they're very good and have a big impact on the development that I'm going to dothese old professors quietly planted a seed in his heart, and constantly guided him: "I want to do things, become a famous family." "At that time, the school was very demanding of them, early self-study, late self-study, countless exams, everyone was working hardBecause of the foundation that accumulated during his college years, and his personal diligence and high standards, he walked faster and farther in the way" Going abroad was a very important turning point in my life "Whether it's basic research or clinical research, my experience abroad has allowed me to reach the summit like a mountaineer, stand on the top of a group of peaks, see its vastness, and know its depth." This is very important It lets you do everything you can do later, you can have a coordinate, know at which level you are at, and in what direction you need to go 1991, Yang Jianxin studied in the United States, in the Nobel Prize winner Dr Michael Brown and Joseph Goldstein are doing ph.D research at the Laboratory His research at the time illustrated the mechanism sREBP1 and 2 regulating fatty acid/cholesterol synthesis and LDL receptor expression, a major achievement published in the world's leading academic journals and entered into authoritative textbooks this is also one of the proud achievements of his life "That was my highest achievement in basic research completed his Ph.D study, he enrolled in the Howard Hughes Institute of Medicine at Harvard University in August 1995 for a three-year postdoctoral study "three-and-a-half years of ph.d're in the doctor, three years of postdoctoral, add up to six and a half years, I have walked the average person at least eight years to complete the road "He felt like he was "going faster." /02/
's idle feelings came out of Harvard, Yang Jianxin entered the pharmaceutical company work his first job at the pharmaceutical company, then known as Tularik, where he worked as an oncologist Here, he has made two very important business deals for the company, which has gone from being a regular innovative drug company to a first-class innovative drug company, and is listed on NASDAQ the two business partnerships, the core strategic partnerships with Medarex and Amgen, are worth more than $125 million Later, Amin spent more than $1 billion on Duraric before it was on the market During this period, Yang Jianxin published several academic papers and obtained 9 patents later, Yang Jianxin left The Duraric, which has become Amgen, to Pfizer as a senior chief scientist At Pfizer, he established the first Oncology and Immunotransformational Medicine Laboratory to support translational medicine for the entire oncology and immunology research pipeline was comfortable working at Pfizer, but Mr Yang "complained": "I'm going to die." "This kind of leisure doesn't make him particularly happy, he's always looking for things to do, trying a lot of other things, like playing ball, skiing, and even spending time researching vegetables and building houses "But i still haven't let my heart really fill." "That year rooted in the heart of that feeling, and constantly drove him to explore their own value in life "Just want to do something." then he joined the internationally renowned CRO company, Covins, as director of clinical oncology medicine, responsible for phase III of international clinical trials, dealing with the world's leading pharmaceutical companies Working at CRO is completely different from pharmaceutical companies THE attributes of THE CRO determine that he must understand, familiarize himself with the entire clinical development process, and master the role of each link and role in the process "My experience at CRO opened my eyes and gave me an intuitive understanding of how the clinical team works, which helped me to return home to build my own clinical team He said however, Mr Covins's busy work did not calm his heart, which had been hiding his feelings In early 2014, Wang Xiaodong, chairman of Baiji Shenzhou, found him he remembers that it was at Fisherman's Wharf in San Francisco, where Wang Xiaodong, the founder of Baiji Shenzhou, invited him to dinner and invited him home by that time, Yang Jianxin had been studying, living and working in the United States for more than twenty years As he prepared to leave Mr Cowens, many American companies extended an olive branch to him He could choose not to return home, and life in the United States was good enough But he always thought about how to do something to make his life meaningful At the same time, the idea of "success" in his bones of traditional Chinese doctors is also beating "People with professional backgrounds like me can find a hundred or so in the United States, but if you return to China, it's estimated to be less than ten, and they can make a greater impact and contribution to China's drug research and development business." Plus, Yang Jianxin was over 40 years old at the time, "this age, do not go back to China to do something, may not want to do a lifetime." "Chinese's "root" in his heart on the scale added not light weight after nearly eight or nine months of deliberation, Yang Jianxin decided to return home /03/
return edited three major challenges
returned to China, And Yang Jianxin soon found that he faced great challenges the first challenge is the difference between the whole clinical research environment in China and abroad, both in terms of understanding of clinical research and the standard of what to do For example, Phase I clinical, which is already exploratory and open-up, he has found that some Chinese researchers may have been too cautious to influence progress second challenge is people " clinical trial experience of talent, the gap in China is not a small point, not only in the number of differences, but also with foreign professionals in the quality gap is also very large He points out that most of the leading clinical studies in the United States are MDs who have undergone medical and biological science training, and That PhD Double (so-called clinical medical scientists) differs greatly in knowledge, experience, ability, and at home in the domestic two team formation experience, so that Yang Jianxin feel the difficulties of recruiting For the first time, he has formed an efficient clinical development team with more than 30 clinical development, project management and operations, medical and safety monitoring, and data management The second time, in less than two years, he has built a large clinical team of more than 70 people with the strong support of the management and personnel departments of Keystone Pharmaceuticals, and the team is growing the extent of the difficulty of both experiences was at one point what he later saw as a major achievement "It's really hard to attract these talented people and get to the point where they can really conduct clinical trials and allow them to think, innovate and do the project quickly, based on the standard process." he stressed that this is a process that requires constant communication and influence Therefore, there must also be a teaching and education mentality "At the same time, I hope that the people on his team will be able to make a huge improvement in their professional abilities and positively influence their careers." third is that China's drug market will pay off on innovative drugs relative to mature markets such as the United States These uncertainties can seriously affect the strategy of clinical development in China That's why, when planning for product development, these uncertainties need to be taken into account and a balanced and secure development strategy developed "This will be a lot more certain of future success He said /04/ Why can go so fast? Yang Jianxin has been senior vice president and head of clinical development department of Baiji Shenzhou since 2014, leading the clinical development team of Baiji Shenzhou In just two and a half years, has conducted and managed more than a dozen international and national clinical trials, completed the first of four candidates for PD-1 monoabinuse, BRAF inhibitors, PARP inhibitors, and BTK inhibitors (including single and combination therapy), and collected critical safety and effective clinical data to achieve clinical proof of drug clinical proof Data from these clinical trials were presented and presented at nearly ten international industry conferences "The first PD-1 from China, which was the first clinical thing to enter international, and proved to be a good PD-1; there's the third, China's first BTK inhibitor in the world, and probably the best BTK inhibitor in the industry right now; and China's first PARP inhibitor, which proves that it's at least as bad as a competition." these, coupled with his later to the cornerstone of the pharmaceutical industry, do China's first full-length PD-L1, have become Yang Jianxin's heart to make himself proud, proud of the achievements Baiji Shenzhou thus became China's most promising biological innovation company at that time Subsequently, Baiji Shenzhou listed on NASDAQ "So it was an accident to make a little money He smiled , after its U.S listing, the clinical research and development team was on a massive scale in the U.S., and Yang Jianxin, who returned from the U.S., did not want to return to a multinational company So he left Baiji Shenzhou and embarked on a new journey This time, he finally chose Keystone Pharmaceuticals " was just seven or eight people at the time, but it had a rich product line of cancer, a large financing, and a CEO candidate Yang Jianxin planned, "If I come, I can re-establish the clinical team, make its products, as soon as possible to benefit the vast number of cancer patients in China." Moreover, in Yang Jianxin's view, Keystone Pharmaceuticals has no baggage, that is, there is no packet of clinical trials already done, and no personnel baggage "In short, put on a light and do what you want." After to Keystone Pharmaceuticals, Yang Jianxin continued his "fast" and, in less than two years, conducted clinical trials of innovative anti-tumor drugs, including targeted and immuno-anti-tumor drugs, and then launched the cornerstone pharmaceutical research and development pipeline to domestic and international markets "We have also introduced four products to conduct registered clinical trials in the country He added it is understood that Cornerstone Pharmaceuticals currently has 14 tumor projects in development, and 8 have been or are about to enter the clinical phase, products include PD-L1, PD-1, CTLA4, MEK, IDH1, KIT and PDGFR alpha, FGFR4, RET, etc., including 3 key registered clinical studies, covering a number of high incidence of cancer adaptation in the Chinese group , just before last week's ESMO meeting, Keystone Pharmaceuticals was fortunate to release preliminary data on the expected first phase of clinical studies At the same time, they not only carry out three international clinical projects in Australia, PD-L1, PD-1 also recently obtained FDA approval, will start clinical studies in the near future , then, what is the reason, so that Yang Jianxin in Baiji Shenzhou, or keystone pharmaceutical industry can go so fast? he makes an analogy: an old Shanghainative who has lived in Shanghai for 50 years may be familiar with the streets of Shanghai, and even if the city changes quickly, he only needs to "update" his message on a map he is familiar with If there is a new what, the old Shanghai people will immediately respond to, where the original is what, what else is around, why this is built .. Similarly, Yang Jianxin has been fighting in the field of oncology for decades, accumulated knowledge and experience, so that he can quickly judge every information, and targeted response or ready to deal with he said that china's new drug research and development is still at a relatively low level, and at the highest level of the world has worked on him, many things do not have much difficulty, in addition to the need to coordinate with third parties to promote things, he and the team only need to their own clinical development strategy and program design as perfect as possible, and in the implementation process to make the ministries closely linked, reduce repetition, the speed is naturally fast "Wait another three or five years, finish me-too, me-better, start to do first-in-class, the real competition began "Yang Jianxin, who has thought ahead of time for three or five years, is very clear about how to prepare for the next phase experts: Yang Jianxin, M.D., Ph.D., Chief Medical Officer of Keystone Pharmaceuticals, Senior Vice President of Clinical Development and Registration